Home LiteratureArticle Details
PMID: 19789839 Published · ppublish English Journal Article Review

The particular relationship between Parkinson's disease and malignancy: a focus on skin cancers.

Journal of neural transmission (Vienna, Austria : 1996) ·Vol. 116 ·No. 11 ·2009-11-00 ·Pages 1503-7

Inzelberg R, Israeli-Korn SD

Abstract

Although the risk for most cancers appears to be relatively low in patients with Parkinson's disease (PD), skin cancers and melanomas occur more frequently in the PD population as compared to controls. This article summarizes the findings of cohort studies on skin cancer in Parkinson's disease. Given that melanoma may precede use of L-dopa, the increased risk of melanoma for PD patients cannot be attributed to L-dopa. On the basis of these observations it may be reasonable to recommend that all patients with PD, whether treated with L-dopa or not, should undergo regular dermatological screening for neoplastic or pre-neoplastic skin lesions, especially melanoma.

MeSH Terms
Antiparkinson Agents/adverse effects Causality Comorbidity Humans Levodopa/adverse effects Mass Screening Melanoma/epidemiology,etiology,physiopathology Parkinson Disease/drug therapy,epidemiology,physiopathology Risk Factors Skin Neoplasms/epidemiology,etiology,physiopathology
Chemicals
Antiparkinson Agents Levodopa
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Inzelberg Rivka
Department of Neurology, The Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Israel. inzelber@post.tau.ac.il
Israeli-Korn Simon D
References (43)
43 references, click to expand
  1. Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature.
    J Am Acad Dermatol. 1997 Aug;37(2 Pt 2):332-6 PMID: 9270541
  2. Skin cancers and precancerous lesions in Parkinson's disease patients.
    Mov Disord. 2007 Jul 30;22(10):1471-1475 PMID: 17516496
  3. Epidemiology of Parkinson's disease in a Japanese city.
    Arch Neurol. 1983 Mar;40(3):151-4 PMID: 6830454
  4. Parkinsonism: onset, progression and mortality.
    Neurology. 1967 May;17(5):427-42 PMID: 6067254
  5. Mortality cancer risk in parkinsonian patients: a population-based study.
    Neurology. 1999 Jan 15;52(2):395-8 PMID: 9932965
  6. Levodopa and melanoma: three cases and review of literature.
    J Neurol Neurosurg Psychiatry. 1985 Jun;48(6):585-8 PMID: 4009196
  7. Levodopa and the risk of melanoma.
    Lancet. 2007 Jan 27;369(9558):257-8 PMID: 17258651
  8. The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel.
    J Neurol. 2009 Mar;256(3):483-7 PMID: 19412725
  9. Malignant melanoma in early Parkinson's disease: the DATATOP trial.
    Mov Disord. 2007 Apr 15;22(5):720-2 PMID: 17373726
  10. Are Parkinson disease patients protected from some but not all cancers?
    Neurology. 2007 Oct 9;69(15):1542-50 PMID: 17699801
  11. Nonfatal cancer preceding Parkinson's disease: a case-control study.
    Epidemiology. 2002 Mar;13(2):157-64 PMID: 11880756
  12. Avoidable cancers in the Nordic countries. Aims and background.
    APMIS Suppl. 1997;76:1-8 PMID: 9462817
  13. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries.
    Mov Disord. 2006 Aug;21(8):1102-8 PMID: 16622854
  14. Lid melanoma and parkinsonism.
    Br J Ophthalmol. 1992 Apr;76(4):246-7 PMID: 1390497
  15. Treatment with levodopa and risk for malignant melanoma.
    Mov Disord. 2007 Jul 15;22(9):1252-7 PMID: 17534943
  16. Parkinson's disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990.
    Neurology. 1994 Oct;44(10):1865-8 PMID: 7936238
  17. Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization.
    J Clin Invest. 2008 Apr;118(4):1380-9 PMID: 18340382
  18. Mortality and cancer incidence in patients with Parkinson's disease.
    J Neurol. 2000 Jun;247(6):429-34 PMID: 10929271
  19. Mortality due to amyotrophic lateral sclerosis and Parkinson's disease among melanoma patients.
    Neuroepidemiology. 2007;28(1):16-20 PMID: 17164565
  20. Low cancer rates among patients with Parkinson's disease.
    Ann Neurol. 1985 May;17(5):505-9 PMID: 4004173
  21. Accelerated growth of malignant melanoma by levodopa in Parkinson's disease and role of the pineal gland.
    Int J Neurosci. 1992 Mar;63(1-2):137-40 PMID: 1342025
  22. Levodopa therapy and malignant melanoma.
    JAMA. 1978 Aug 11;240(6):554-5 PMID: 671667
  23. Malignant melanoma and other types of cancer preceding Parkinson disease.
    Epidemiology. 2006 Sep;17(5):582-7 PMID: 16837822
  24. Levodopa therapy and the risk of malignant melanoma.
    Ann Pharmacother. 2000 Mar;34(3):382-5 PMID: 10917387
  25. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology?
    J Neurol Neurosurg Psychiatry. 1995 Mar;58(3):293-9 PMID: 7897409
  26. Genetic analysis of LRRK2 mutations in patients with Parkinson disease.
    J Neurol Sci. 2006 Dec 21;251(1-2):102-6 PMID: 17097110
  27. Prospective case-control study of nonfatal cancer preceding the diagnosis of Parkinson's disease.
    Cancer Causes Control. 2007 Sep;18(7):705-11 PMID: 17562193
  28. Risk of cancer after the diagnosis of Parkinson's disease: a historical cohort study.
    Mov Disord. 2005 Jun;20(6):719-25 PMID: 15704188
  29. Occurrence of different cancers in patients with Parkinson's disease.
    BMJ. 1995 Jun 10;310(6993):1500-1 PMID: 7787596
  30. Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literature.
    Melanoma Res. 2006 Jun;16(3):201-6 PMID: 16718266
  31. Parkinson's disease and cancer: insights for pathogenesis from epidemiology .
    Ann N Y Acad Sci. 2009 Feb;1155:324-34 PMID: 19250224
  32. Are Parkinson disease patients protected from some but not all cancers?
    Neurology. 2008 Nov 11;71(20):1650; author reply 1650-1 PMID: 19001259
  33. Atypical cancer pattern in patients with Parkinson's disease.
    Br J Cancer. 2005 Jan 17;92(1):201-5 PMID: 15583688
  34. Pigmentation as a clue to understanding Parkinson's disease and melanoma.
    Ann Neurol. 2009 Jun;65(6):759; author reply 759 PMID: 19557863
  35. The use of L-dopa and carbidopa in metastatic malignant melanoma.
    J Invest Dermatol. 1991 Jan;96(1):85-7 PMID: 1987300
  36. Genetic determinants of hair color and Parkinson's disease risk.
    Ann Neurol. 2009 Jan;65(1):76-82 PMID: 19194882
  37. The physiology of pigmented nevi.
    Pediatrics. 1999 Oct;104(4 Pt 2):1042-5 PMID: 10506262
  38. Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence?
    Parkinsonism Relat Disord. 2003 Aug;9(6):321-7 PMID: 12853231
  39. A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease.
    Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1260-5 PMID: 17548694
  40. Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models.
    Clin Cancer Res. 2008 Apr 15;14(8):2502-10 PMID: 18413843
  41. Problem situations in the treatment of paralysis agitans.
    J Am Med Assoc. 1954 Oct 16;156(7):680-4 PMID: 13201370
  42. Multiple primary melanoma following administration of levodopa.
    Arch Pathol. 1972 Jun;93(6):556-61 PMID: 5025039
  43. Prevalence of neoplasms and causes of death in paralysis agitans. A necropsy study.
    Neurology. 1973 Mar;23(3):215-22 PMID: 4144412
Article Info
Journal
Journal of neural transmission (Vienna, Austria : 1996)
Abbr.
J Neural Transm (Vienna)
ISSN
1435-1463
DOI
10.1007/s00702-009-0322-x
Email
inzelber@post.tau.ac.il
Published
2009-11-00
Pages
1503-7
Language
English
Region
Austria
NLM ID
9702341
Subset
IM
External Links
PubMed source DOI: 10.1007/s00702-009-0322-x View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2